Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models

被引：0

作者：

Quagliariello, Vincenzo

Cortellino, Salvatore

Delfanti, Gloria

Di Mauro, Annabella

Tatangelo, Fabiana

Spagnolo, Vanessa

Visco, Euplio

Casorati, Giulia

Chiodoni, Claudia

Della Bona, Paolo

Blazevits, Olga

Ascierto, Paolo Antonio

Maurea, Nicola

Longo, Valter

机构：

[1] IRCCS Fdn G Pascale, Naples, Italy

[2] IRCCS CROB, Rionero In Vulture, Italy

[3] IRCCS S Raffaele Sci Inst, Milan, Italy

[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Pathol Unit, Naples, Italy

[5] Natl Canc Inst Naples, Naples, Italy

[6] IFOM, Milan, Italy

[7] San Raffaele Inst, Milan, Italy

[8] Fdn IRCCS Isttuto Nazl Tumori, Milan, Italy

[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[10] Ist Nazl Studio & Cura Tumori Fdn G Pascale IRCCS, Div Cardiol, Naples, Italy

[11] IFOM FIRC Inst Mol Oncol, Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

12029

引用

页数：1

共 50 条

[41] ENHANCED ANTI-TUMOR EFFECTS OF ANTI-CTLA-4 ANTIBODY AND ANTI-PD-1 ANTIBODY TO KIDNEY CANCER MODEL IN MICE
Motoshima, Takanobu
Komohara, Yoshihiro
Hasita, Horlad
Kawano, Yoshiaki
Wada, Yoshihiro
Takeya, Motohiro
Eto, Masatoshi
JOURNAL OF UROLOGY, 2014, 191 (04): : E372 - E373
[42] Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
Passat, Tilda
Touchefeu, Yann
Gervois, Nadine
Jarry, Anne
Bossard, Celine
Bennouna, Jaafar
BULLETIN DU CANCER, 2018, 105 (11) : 1033 - 1041
[43] Effect of radiofrequency ablation (RFA) combined with anti-CTLA-4 and anti-PD1 in a preclinical melanoma model.
Franco-Mahecha, Olga L.
Christou, Anna
Mauda-Havakuk, Michal
Katti, Prateek
Pritchard, William F.
Karanian, John W.
Wood, Bradford J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[44] Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
Xiang, Ze
Li, Jiayuan
Zhang, Zhengyu
Cen, Chao
Chen, Wei
Jiang, Bin
Meng, Yiling
Wang, Ying
Berglund, Bjoern
Zhai, Guanghua
Wu, Jian
FRONTIERS IN PHARMACOLOGY, 2022, 13
[45] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Pollack, M. H.
Betof, A.
Dearden, H.
Rapazzo, K.
Valentine, I.
Brohl, A. S.
Ancell, K. K.
Long, G. V.
Menzies, A. M.
Eroglu, Z.
Johnson, D. B.
Shoushtari, A. N.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
[46] Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
Aya Moreno, F.
Fernandez-Martinez, A.
Gaba, L.
Victoria, I.
Arance Fernandez, A. M.
ANNALS OF ONCOLOGY, 2015, 26 : 6 - 6
[47] Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
[48] The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Katy K. Tsai
Adil I. Daud
Drugs, 2015, 75 : 563 - 575
[49] The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Tsai, Katy K.
Daud, Adil I.
DRUGS, 2015, 75 (06) : 563 - 575
[50] Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
Sone, Kenbun
Kukita, Asako
Masui, Yuri
Yamada, Daisuke
Shinozaki-Ushiku, Aya
Kawata, Akira
Taguchi, Ayumi
Miyamoto, Yuichiro
Tanikawa, Michihiro
Iriyama, Takayuki
Tsuruga, Tetsushi
Osuga, Yutaka
MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (03)

← 1 2 3 4 5 →